Author(s): Vinhas de Souza M, Keller-Stanislawski B, Blake K, Hidalgo-Simon A, Arlett P, et al.
The occurrence of severe adverse events such as progressive multifocal leukoencephalopathy (PML) has the potential to limit the benefits of highly efficacious medicines being developed to fulfill unmet clinical needs across therapeutic areas. Following an Expert meeting in London in July 2011 (http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500111562.pdf), a research agenda, highlighting methodological, clinical, and communication elements, to mitigate the risk and improve the management of drug-induced PML has been agreed upon.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/22378158
Author(s): Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, et al.
Author(s): Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, et al.
Author(s): Costelloe L, Jones J, Coles A
Author(s): McFarland HF, Martin R
Author(s): Curtin F, Hartung HP
Author(s): Sandberg-Wollheim M, Kornmann G, Bischof D, Moraga MS, Hennessy B, et al.
Author(s): Achiron A, Barak Y, Gail M, Mandel M, Pee D, et al.
Author(s): Riminton DS, Hartung HP, Reddel SW
Author(s): Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, et al.
Author(s): Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al.
Author(s): Confavreux C, Vukusic S
Author(s): Wasson S, Zafar MN, Best J, Reddy HK
Author(s): Curtin F, Schulz P
Author(s): Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC
Author(s): Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, et al.
Author(s): Curtin F, Lang AB, Perron H, Laumonier M, Vidal V et al.
